



Somaxon Pharmaceuticals, Inc. To Present At The 18th Annual Roth Capital Partners Growth Stock Conference

SAN DIEGO, CA – Feb. 15, 2006 – Somaxon Pharmaceuticals, Inc., (NASDAQ: SOMX) today announced that Kenneth Cohen, President and Chief Executive Officer, will present a company update at the 18th Annual Roth Capital Partners Growth Stock Conference in Dana Point, CA on Tuesday, February 21, 2006 at 11:30 a.m. PST.

Interested parties will be able to listen to a live webcast of the presentation by visiting www.somaxon.com and connecting via a link to the Roth Dana Point Conference at <http://www.wsw.com/webcast/roth7/somx/>. A replay of the webcast will be archived for three months.

About Somaxon Pharmaceuticals

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon's lead product, SILENORTM (doxepin hydrochloride) 1mg, 3mg, 6mg, is in Phase III clinical trials for the treatment of insomnia.

Contact:

Meg McGilley, CFO (858.509.3670), or Rob Whetstone, Pondel/Wilkenson, Inc. (310.279.5980).

Web site: www.somaxon.com.